Skip to content

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

VTGN Vistagen Therapeutics, Inc. Common Stock
$0.59 4.69% +0.03
Notify me if price changes either direction
Interactive Brokers Logotype

Buy VTGN stocks now with Interactive Brokers – the most advanced investment platform

Contents
  • Performance
  • Key stats
  • Financials
  • US politician trades
Loading

Key Stats

Market cap. 22.9M
Enterprise value -53263640
Trailing PE -0.34700599973073
Forward PE -0.45382112
PEG Ratio -0.012145209990576
Enterprise to EBITDA 0.816
Enterprise to revenue -73.875
Price to book MRQ 0.32719812
Price to sales TTM 30.577478

Financials

Fiscal Year Ends 2025-03-31
Most Recent Quarter (MRQ) 2025-09-30
Revenue (TTM) 721.0K
EBITDA -65301000
Diluted EPS TTM -1.92
Total Cash (MRQ) 77.2M
Current ratio (MRQ) 5.785
Operating Cash Flow (TTM) -52947000

VTGN trades by the US politicians

Percentage
0% 0 sells
100% 0 buys
Amount
$0 0 sells
$0 0 buys
In the last 0 months

Recent VTGN News

Home

IMPORTANT NOTICE

Finbold is a news and information website. This Site may contain sponsored content, advertisements, and third-party materials, for which Finbold expressly disclaims any liability.

RISK WARNING: Cryptocurrencies are high-risk investments and you should not expect to be protected if something goes wrong. Don’t invest unless you’re prepared to lose all the money you invest. (Click here to learn more about cryptocurrency risks.)

By accessing this Site, you acknowledge that you understand these risks and that Finbold bears no responsibility for any losses, damages, or consequences resulting from your use of the Site or reliance on its content. Click here to learn more.